What’s Hot – GYG, ROC, EXR, NXT, LIT, ECT, OD6 & PHO
What’s Not – ATX
What’s Hot
GYG – Guzman y Gomez Limited today closed up 19% to finish at $18.02 on $17.6m stock traded. The reason they were up today was because they released its quarterly results which highlighted strong network sales growth. The increase in network sales was driven by restaurant network expansion, with five new GYG restaurants opening in Australia.
ROC – RocketBoots Limited today closed up 14% to finish at 39.5c on $290k stock traded. There was no news out today but last week they announced a new ~A$3.3m activation contract was executed for a previously announced global SaaS (software-as-a-service) agreement.
EXR – Elixir Energy Limited today closed up 14% to finish at 12c on $2.2m stock traded. There was no news out today but last week they announced the completion of a seismic survey over Teelba 2D located in the Taroom Trough, QLD.
NXT – NEXTDC Limited today closed up 12% to finish at $12.60 on $74m stock traded. The reason they were up today was because they announced the launch of a A$1B wholesale offer of subordinated hybrid securities to support its growth strategy.
LIT – Livium Limited today closed up 11% to finish at 1c on $140k stock traded. There was no news out today but back in late February they announced the execution of a five-year lease for a new large-scale Melbourne recycling facility.
ECT – Environmental Clean Technologies Limited today closed up 11% to finish at 9.1c on $190k stock traded. The reason they were up today was because they announced an expanded licence agreement was entered with William Marsh Rice University.
OD6 – OD6 Metals Limited today closed up 10% to finish at 11c on $320k stock traded. The reason they were up today was because they announced an exploration update from its recently acquired Quinn Fluorspar Project located in Nevada.
PHO – PhosCo Limited today closed up 10% to finish at 14.5c on $320k stock traded. The reason they were up today was because they announced drilling results from its Gasaat Phosphate Project located in Tunisia.
What’s Not
ATX – Amplia Therapeutics Limited today closed down 38% to finish at 15c on $8.5m stock traded. The reason they were down today was because they announced it is halting further recruitment in the AMPLICITY clinical trial in advanced pancreatic cancer.
The AMPLICITY clinical trial is investigating its lead drug narmafotinib in combination with the chemotherapy regimen modified FOLFIRINOX (mFOLFIRINOX).
Rats Rant – IMPORTANT INFORMATION
The idea of this report is to be informative and hopefully point out some stocks that you wouldn’t ordinarily have seen during the day, maybe even have a laugh too.This report IS NOT personal advice. Sanlam Private Wealth Pty Ltd DOES NOT PROVIDE personal advice, Sanlam Private Wealth provides General Financial Product Advice.All advice included in The Rat’s Rant is General Advice. Please refer to the General Advice Warning. The views expressed in this report are my views and may not necessarily reflect the same views as Sanlam Private Wealth.It is very important to refer to the ASX website for information on any companies / stock that are contained in this report and as always please consult your financial adviser before acting.
Important Notice
Rat Consulting Pty Ltd (ABN 81 148 181 588 ) Authorised Representative (No 001281456) of Sanlam Private Wealth Ltd (ABN 18 136 960 775) holder of Australian Financial Services Licence (AFSL 337 927).